Billionaires Julian and Felix Baker, with a net worth of $2.8 billion each, run Baker Bros. Advisors, a hedge fund that focuses on biotech stocks. Their recent 13F holdings report revealed $9.36 billion in assets across 95 securities. In Q4 2024, the firm made over 40 moves, including significant adjustments in prominent biotech investments. They notably sold 80% of their holdings in DBV Technologies despite its advanced clinical trial stage for an immunotherapy product, reflecting the volatile nature of biotechnology investments.
Baker Bros. Advisors, led by billionaires Julian and Felix Baker, manages nearly $9.36 billion in biotech stocks, showcasing their influence in the sector.
The firm made 41 moves in Q4 2024, but one notable change involved selling 80% of its holdings in a promising French biopharmaceutical firm.
Collection
[
|
...
]